Lapatinib, a dual EGFR/HER-2 tyrosine kinase inhibitor, has been found to exert significant biologic effects on the inhibition of signaling pathways to promote breast cancer cell proliferation and survival, especially in terminal, recurrent, or metastatic breast cancer patients who had experienced anthracyclines treatment (85). This evidence concerns the gene ERBB2 and breast cancer.